Skip to content

A Prospective Comparison of Cardiac Troponin T and Troponin I in the Diagnosis of Myocardial Infarction

A Prospective Comparison of Cardiac Troponin T and Troponin I in the Diagnosis of Myocardial Infarction

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04087538
Enrollment
300
Registered
2019-09-12
Start date
2021-07-01
Completion date
2024-04-01
Last updated
2023-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Infarction

Keywords

troponin

Brief summary

The rising number of patients with chest pain without myocardial infarction has made accurate diagnosis important. Unnecessary invasive coronary angiographies are increasingly prevalent. These are both costly and lead to rare but serious adverse events. Recent studies suggest cardiac Troponin I is more cardiac specific than cardiac Troponin T. In this study we will investigate whether using cardiac Troponin I lead to fewer unnecessary procedures in clinical practice (i.e. invasive coronary angiography and non-invasive tests)

Interventions

DIAGNOSTIC_TESTTroponin T and I

Does the use of troponin T or I increase the number of patients referred to coronary angiography

Sponsors

Herlev Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Admitted to either Herlev-Gentofte or Amager-Hvidovre Hospital * Clinically suspected of NSTEMI * Referred to invasive coronary angiography (ICA) * Recieved at least one measurement of either troponin

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
Specificity for MI0The difference in specificity of cardiac Troponin and I in detecting patients with significant CAD. The specificity will be defined as the proportion of patients with no significant CAD on ICA correctly identified as low-risk patients and not referred to ICA upon the review by the senior cardiologists
Cost-effectiveness0The cost-effectiveness of using cardiac Troponin T compared to cardiac Troponin I. This will be defined by the number of patients sent to ICA and the associated costs of this.

Secondary

MeasureTime frameDescription
Sensitivity for MI0A safety outcome of difference in sensitivity of cardiac Troponin T and cardiac Troponin I in the detection of patients with significant coronary artery disease. The sensitivity is defined as the proportion of patients with significant coronary artery disease that were referred to ICA upon review by the senior cardiologists
Elevated troponin without CAD0The difference in the proportion of patients with elevated cardiac Troponin T or cardiac Troponin I above the 99th percentile with no significant CAD on ICA
Number of MIs0The difference in the number of patients diagnosed with MI for each cardiac Troponin
PPV and NPV0The difference in positive predictive value and negative predictive value of each cardiac Troponin

Countries

Denmark

Contacts

Primary ContactKasper Iversen, Dmsc
Kasper.karmark.iversen@regionh.dk28712753

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026